Syncom Formulations logo

Syncom Formulations

SYNCOMF NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹1,758 Cr
Volatility
Moderate
P/E Ratio
21.62
EBITDA
₹77.43 Cr
Return on Equity
14.45%
Debt to Equity
0
Book Value
₹4.41
52W High
₹22.59
52W Low
₹10.21

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.2% CAGR over last 5 years

Weaknesses

2
  • Earnings include an other income of Rs.32.8 Cr.
  • Working capital days have increased from 103 days to 164 days

Growth Rate

Revenue Growth
1.4% lower than 3Y
Net Income Growth
58.4% higher than 3Y
Cash Flow Change
493% higher than 3Y
ROE
64.39% higher than 3Y
ROCE
45.46% lower than 3Y
EBITDA Margin (Avg.)
0.27% higher than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
59
62
63
73
87
101
127
148
117
121
115
134
125
Expenses
53
56
57
64
76
90
112
131
101
103
93
113
99
Operating Profit
6
6
7
9
10
12
15
17
16
19
21
21
26
OPM %
10%
10%
11%
12%
12%
12%
11%
12%
14%
15%
18%
16%
21%
Other Income
2
4
4
3
1
4
4
7
6
5
5
14
8
Interest
1
1
1
1
0
0
0
0
0
0
0
0
0
Depreciation
1
1
1
1
1
1
1
1
1
1
1
2
2
PBT
6
8
9
9
10
15
17
23
20
22
25
33
32
Tax %
27%
24%
25%
27%
24%
25%
24%
24%
22%
25%
25%
25%
23%
Net Profit
4
6
6
7
8
11
13
18
16
17
19
25
25
EPS in Rs
0.05
0.07
0.07
0.07
0.08
0.12
0.14
0.19
0.17
0.18
0.2
0.26
0.26
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
173
184
185
159
187
206
245
216
222
257
461
487
495
Expenses
155
167
168
147
175
189
207
196
202
229
407
409
407
Operating Profit
18
17
16
12
12
17
38
20
20
28
54
77
87
OPM %
11%
9%
9%
7%
6%
8%
16%
9%
9%
11%
12%
16%
18%
Other Income
1
3
3
4
5
5
7
12
15
13
17
31
33
Interest
0
0
0
0
0
1
0
2
3
5
1
1
1
Depreciation
3
3
3
4
4
4
4
4
5
5
5
7
7
PBT
16
16
16
12
13
17
41
26
27
32
65
101
112
Tax %
38%
36%
33%
28%
12%
18%
28%
24%
24%
26%
24%
24%
—
Net Profit
10
10
11
9
11
14
29
20
20
24
49
76
85
EPS in Rs
0.13
0.13
0.14
0.11
0.14
0.18
0.37
0.23
0.21
0.25
0.52
0.81
0.9
Div. Payout %
16%
15%
15%
0%
0%
0%
0%
13%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
78
78
78
78
78
78
79
86
94
94
94
94
Reserves
22
31
36
44
55
68
109
136
162
192
246
318
Borrowings
6
6
12
12
9
2
62
58
83
72
4
1
Other Liabilities
31
61
48
37
32
33
42
28
38
33
66
116
Total Liabilities
138
175
175
171
173
181
292
308
377
392
410
529
Fixed Assets
46
46
85
89
89
93
91
94
91
120
125
184
CWIP
0
5
0
1
0
0
0
6
26
0
0
0
Investments
6
23
1
2
2
1
11
43
64
66
93
109
Other Assets
85
101
89
79
83
87
189
165
196
206
192
237
Total Assets
138
175
175
171
173
181
292
308
377
392
410
529
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
24
17
-2
4
6
-2
16
10
-6
23
58
Investing
1
-23
-8
-2
2
2
-75
-27
-45
84
-18
-51
Financing
1
-2
-2
-2
0
-7
72
8
35
-15
-68
-3
Net Cash Flow
2
-1
6
-6
7
1
-5
-2
1
63
-63
4
Free Cash Flow
-3
16
9
-8
10
4
-5
5
-10
-14
13
47
CFO/OP
32
176
128
13
66
61
24
113
86
6
70
105
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
66
91
91
87
81
77
112
114
124
132
85
81
Inventory Days
34
43
29
37
37
39
51
51
53
49
49
81
Days Payable
63
130
92
75
57
49
66
36
52
33
51
96
Cash Conversion Cycle
37
4
27
49
61
67
96
129
124
148
83
66
Working Capital Days
84
40
45
75
74
88
28
33
-4
51
95
164
ROCE %
16%
15%
14%
9%
9%
12%
21%
11%
10%
10%
19%
27%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Syncom Formulations insights

29 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Shareholding Pattern

FIIs0.35%Promot.50.57%Others4.18%Public44.90%As ofJun 2026

Documents

Frequently Asked Questions about Syncom Formulations

What does Syncom Formulations (India) Ltd do?
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]
Where is Syncom Formulations (India) Ltd (SYNCOMF) listed?
Syncom Formulations (India) Ltd trades as SYNCOMF on the NSE and under code 524470 on the BSE.
Which sector does Syncom Formulations (India) Ltd belong to?
Syncom Formulations (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd has a market capitalisation of ₹1,758 Cr, which places it in the Small Cap band.
What is the PE ratio of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd trades at a PE ratio of 21.62, against a book value of ₹4.41 per share.
What is the 52-week high and low of Syncom Formulations (India) Ltd?
Over the last 52 weeks Syncom Formulations (India) Ltd has traded between ₹10.21 and ₹22.59.
Does Syncom Formulations (India) Ltd pay dividends?
Syncom Formulations (India) Ltd has a dividend yield of 0.52%.
What is the Return on Equity (ROE) of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd reported a return on equity of 14.45%. Its debt-to-equity ratio is 0.00.

Company Information

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]

Website syncomformulations.com
CEO Mr. Ankit Kedarmal Bankda
Employees 744
Listed 2022-11-18
Face Value ₹ 1
Issued Size 94,00,00,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SYNCOMF.md for Syncom Formulations (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List